{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(6)"],"submitter":["Sawaf B"],"pubmed_abstract":["Background
Ulcerative colitis (UC) is a chronic inflammatory disease affecting ~1.5 million individuals, causing significant impairment in quality of life, psychological well-being, and healthcare burden. Using indirect meta-analysis, this study compared the efficacy and safety of anti-interleukin (IL)-12/23 and IL-23 agents vs. placebo and each other, during induction and maintenance in moderate-to-severe UC.Methods
A systematic search of PubMed, Cochrane, Scopus, Web of Science, and ClinicalTrials. gov was conducted on October 1, 2024. The randomized controlled trials (RCTs) included evaluated ustekinumab, mirikizumab, risankizumab, and guselkumab. The primary outcomes were clinical remission and endoscopic improvement at both induction and maintenance endpoints. Odds rat"],"journal":["Annals of gastroenterology"],"pagination":["648-660"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12829535"],"repository":["biostudies-literature"],"pubmed_title":["Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis."],"pmcid":["PMC12829535"],"pubmed_authors":["Hallak Y","Regueiro M","Beshr MS","Elhadi M","Batikh E","Hayek MA","Alom M","Shibani M","Alsoud D","Kassem A","Salam AH","Alastal Y","Sawaf B","Shembesh RH","Abbarh S"],"additional_accession":[]},"is_claimable":false,"name":"Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.","description":"Background
Ulcerative colitis (UC) is a chronic inflammatory disease affecting ~1.5 million individuals, causing significant impairment in quality of life, psychological well-being, and healthcare burden. Using indirect meta-analysis, this study compared the efficacy and safety of anti-interleukin (IL)-12/23 and IL-23 agents vs. placebo and each other, during induction and maintenance in moderate-to-severe UC.Methods
A systematic search of PubMed, Cochrane, Scopus, Web of Science, and ClinicalTrials. gov was conducted on October 1, 2024. The randomized controlled trials (RCTs) included evaluated ustekinumab, mirikizumab, risankizumab, and guselkumab. The primary outcomes were clinical remission and endoscopic improvement at both induction and maintenance endpoints. Odds rat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov-Dec","modification":"2026-06-13T05:18:07.885Z","creation":"2026-06-13T03:08:48.94Z"},"accession":"S-EPMC12829535","cross_references":{"pubmed":["41586395"],"doi":["10.20524/aog.2025.1009"]}}